<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05081648</url>
  </required_header>
  <id_info>
    <org_study_id>HD-MuST-01-PT</org_study_id>
    <nct_id>NCT05081648</nct_id>
  </id_info>
  <brief_title>Must Cannulation Technique of Vascular Access in Patients Undergoing Haemodialysis: Contributions for a Safe Nursing Intervention</brief_title>
  <acronym>MuST</acronym>
  <official_title>A Randomised Control Trial of MuST Technique for Vascular Access Cannulation in Hemodialysis Patients: Contributions for a Safe Nursing Intervention</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fresenius Medical Care Deutschland GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Lisbon</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fresenius Medical Care Deutschland GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aims of this study are to:&#xD;
&#xD;
        -  Determine the AVF (arteriovenous fistula) survival of patients submitted to MuST&#xD;
           compared to those submitted to RL (rope-ladder).&#xD;
&#xD;
        -  Determine the AVF (arteriovenous fistula) complication rate of patients submitted to&#xD;
           MuST compared to those submitted to RL (rope-ladder).&#xD;
&#xD;
        -  Analyze the intensity of pain perceived by the patient with each cannulation technique&#xD;
           under study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The MuST is based on the association between the RL technique in that it uses the entire&#xD;
      length of the available vessel through progressive rotation, and the buttonhole (BH)&#xD;
      cannulation technique since there are three specific cannulation sites for each cannulation&#xD;
      day during the week, meaning that each site is only cannulated once a week (allowing the&#xD;
      puncture site to heal in between cannulations).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 11, 2021</start_date>
  <completion_date type="Anticipated">September 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>multiple-center, prospective, non-blind, parallel-group, randomized controlled</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Vascular access survival rate</measure>
    <time_frame>12 months after start of study</time_frame>
    <description>Vascular access (VA) survival rate at 12 months and determined by the percentage of fistulas in use from the beginning of the study to the date of the first clinical intervention by angioplasty or vascular surgery, to maintain or restore patency - &quot;unassisted patency&quot;.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Arteriovenous fistula survival rate</measure>
    <time_frame>12 months after start of study</time_frame>
    <description>Arteriovenous fistula (AVF) survival rate at 12-month and determined by the percentage of fistulas in use from the study start to the date of access abandonment due to dysfunction, patient abandonment, or death, treatment change modality or study end.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Chronic Kidney Diseases</condition>
  <condition>Hemodialysis</condition>
  <condition>Vascular Access Complication</condition>
  <condition>Hemodialysis Access Failure</condition>
  <condition>Arteriovenous Fistula</condition>
  <arm_group>
    <arm_group_label>Intervention group: Multiple Single Cannulation Technique (MuST)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group: Rope-ladder cannulation technique (RL)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>CT MuST</intervention_name>
    <description>Multiple Single Cannulation Technique (MuST): Experimental technique</description>
    <arm_group_label>Intervention group: Multiple Single Cannulation Technique (MuST)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Rope-ladder cannulation technique</intervention_name>
    <description>Standard cannulation technique( Rope-ladder)</description>
    <arm_group_label>Control group: Rope-ladder cannulation technique (RL)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Voluntarily agree to participate in the study and sign an informed consent;&#xD;
&#xD;
          -  Are on a regular haemodialysis (HD) program with three weekly sessions;&#xD;
&#xD;
          -  AVF has been in use for at least 4 weeks without incident;&#xD;
&#xD;
          -  AVF with blood flow (Qa) â‰¥500 mL/min evaluated by thermodilution;&#xD;
&#xD;
          -  AVF paths allow cannulations along the entire length of the vein with at least 6 cm of&#xD;
             distance between bevels, or two distinct areas of 3 cm in length;&#xD;
&#xD;
          -  Adult patients&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Those who decline to take part;&#xD;
&#xD;
          -  Those who have undergone angiography or surgical intervention in the last 4 months in&#xD;
             the AVF in use;&#xD;
&#xD;
          -  Those who have undergone three or more interventions in the AVF in use;&#xD;
&#xD;
          -  Those with use of anesthetic creams at cannulation sites.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ricardo Peralta dos Santos</last_name>
    <phone>+351 229 438 280</phone>
    <email>ricardo.peralta@fmc-ag.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anna Wammi</last_name>
    <phone>+4961726097634</phone>
    <email>anna.wammi@fmc-ag.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>NephroCare Coimbra</name>
      <address>
        <city>Coimbra</city>
        <zip>3025-04</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <contact>
      <last_name>Nuno Gomes</last_name>
      <phone>+351 239 499 240</phone>
      <email>nuno.gomes@fmc-ag.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nephrocare Montijo</name>
      <address>
        <city>Montijo</city>
        <zip>2870-281</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <contact>
      <last_name>Antero de Matos</last_name>
      <phone>+351 212 308 58</phone>
      <email>antero.matos@fmc-ag.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>NephroCare Vila Nova de Gaia</name>
      <address>
        <city>Vila Nova De Gaia</city>
        <zip>4430-703</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <contact>
      <last_name>Sandra Lima</last_name>
      <phone>+351 227 157 130</phone>
      <email>sandra.lima@fmc-ag.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Portugal</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>October 5, 2021</study_first_submitted>
  <study_first_submitted_qc>October 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 18, 2021</study_first_posted>
  <last_update_submitted>October 5, 2021</last_update_submitted>
  <last_update_submitted_qc>October 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Kidney Disease</keyword>
  <keyword>Hemodialysis</keyword>
  <keyword>Vascular access</keyword>
  <keyword>Vascular Access Complication</keyword>
  <keyword>Rope-ladder</keyword>
  <keyword>Cannulation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Arteriovenous Fistula</mesh_term>
    <mesh_term>Fistula</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

